Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb14045 · 1 trial · 4 indications
Treatment-related adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| XmAb14045 | EXPERIMENTAL | Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks |
| Name | Type | Description |
|---|---|---|
| XmAb14045 | BIOLOGICAL | Administered IV weekly up to 8 weeks, with or without step-up dosing |
Inclusion Criteria: * Diagnosis of 1 of the following diseases: * Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia) * B-cell ALL * BPDCN * CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor thera...
XmAb14045 is an investigational monoclonal antibody being studied for Acute Myelogenous Leukemia and other CD123-expressing hematologic malignancies. It was evaluated in a Phase 1 trial that also enrolled patients with B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, and blast crisis.
XmAb14045 is developed by Xencor, Inc., which trades on the Nasdaq under the ticker XNCR. Xencor is the sponsor of the clinical program for this monoclonal antibody.
XmAb14045 is in Phase 1 development. Its single clinical trial, NCT02730312, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
XmAb14045 was studied in one Phase 1 trial, NCT02730312, titled a Phase 1 study to evaluate safety and tolerability in patients with CD123-expressing hematologic malignancies. The trial enrolled 120 patients in the United States and is now completed.
XmAb14045 targets CD123, an antigen expressed on hematologic malignancies. The Phase 1 trial NCT02730312 specifically enrolled patients with CD123-expressing cancers, including Acute Myelogenous Leukemia.